Heersche et al explored single-nucleotide polymorphisms in genes related to the metabolism of alectinib to identify patients at risk for toxicity. Alectinib is primarily metabolized into the active metabolite M4. Both compounds are for 40% to 50% metabolized by CYP3A4. Variants in which genes predicted for higher rates of toxicity?